Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,867 matching trials from the live ClinicalTrials.gov search.

Filters: Chapel Hill, North Carolina Clear all

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Healthy Men Age 50 Who Are Considering PSA Screening
Interventions: DESI for home viewing, DESI for viewing at Shared Medical Appointment, Option of SMA and DESI or DESI only; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 2,521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Palo Alto, California • Chapel Hill, North Carolina

Conditions: Obesity, Overweight, Overweight and Obesity
Interventions: Core Behavioral Weight Loss (BWL) Intervention, Behavior Change Technique 1 Message (Action Planning), Behavior Change Technique 2 Message (Discrepancy between Current Behavior and Goal), Behavior Change Technique 3 Message (Feedback on Outcome of Behavior), Behavior Change Technique 4 Message (Social Support), Behavior Change Technique 5 Message (Social Comparison), Behavior Change Technique 6 Message (Social Reward), Behavior Change Technique 7 Message (Focus on Past Success); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 39 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer, Nausea and Vomiting
Interventions: aprepitant, cyclophosphamide, placebo; Drug · Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Burns, Wound Heal, Wounds and Injuries
Interventions: DeepView SnapShot Portable (DV-SSP); Device
Lead sponsor: SpectralMD; Industry
Eligibility: Not listed
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 17 more

Conditions: HIV-1 Infection
Interventions: Vorinostat; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 87
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 77 more

Conditions: Breast Cancer
Interventions: Engagement in Physical Activity, Questionnaires; Behavioral · Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 21 Years to 99 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Enterobacteriaceae Infections, Community-Acquired Infections, Healthcare Associated Infection, Carbapenem-Resistant Enterobacteriaceae Infection
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 2,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Neuroblastoma
Interventions: filgrastim, sargramostim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, conventional surgery, neoadjuvant therapy; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 2011
U.S. locations: 207
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions: FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 26
States / cities: Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more

Conditions: Opioid Dependence, Opioid Withdrawal
Interventions: Intranasal Oxytocin Spray, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Interventions: Nivolumab, Azacitidine, Post Treatment Surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Up to 39 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 19 more

Conditions: Lupus
Interventions: BMS-931699, Placebo matching BMS-931699; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 25
States / cities: Huntsville, Alabama • Fullerton, California • Long Beach, California + 22 more

Conditions: Crohn Disease
Interventions: Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg); Biological
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more

Conditions: Peanut Allergy
Interventions: AR101 - Peanut protein capsule; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 26 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more

Conditions: Preterm Birth Complication, Preterm Birth, Preterm Birth Recurrence, Preeclampsia, Preeclampsia (PE), Hypertensive Disorders of Pregnancy, Support Program, Stress, Resilience, Psychological, Empowerment, Patient, Emotional Stress, Pregnancy, Pregnancy Complications, Pregnancy Induced Hypertension, Neonates and Preterm Infants, Cervical Insufficiency, Social Determinants of Health (SDOH), Cervical Shortening, Disparities in Pregnancy Complications, Disparities, Prenatal Care, Care Coordination
Interventions: Care coordination, Electronic massage, support gift #1, Support gift #2, Support gift #3, Support gift #4, Additional PTBCARE+ support, Stress reduction toolkit - Visit 1 (V1), PTBCARE+ mobile application (app) and website, Sleep, meditation, and Wellness app, Emergency low blood sugar kit, Low dose aspirin (LDA), Visit #2 Stress Reduction Toolkit; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-alcoholic Steatohepatitis
Interventions: Placebo, Silymarin 700 mg, Silymarin 420 mg; Other · Drug
Lead sponsor: Madaus Inc; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 6
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Post Thrombotic Syndrome, Deep Vein Thrombosis, Venous Stasis Syndrome, Venous Insufficiency, Postphlebitic Syndrome
Interventions: VeinOPlus; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Crohn's Disease
Interventions: Risankizumab SC, Placebo for risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 79
States / cities: Sun City, Arizona • Corona, California • Coronado, California + 65 more

Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions: Kidney Biopsy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Up to 80 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 39
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: Myelodysplastic Syndrome
Interventions: vadastuximab talirine, Azacitidine, Placebo (for 33A); Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 34
States / cities: Gilbert, Arizona • Los Angeles, California • Aurora, Colorado + 29 more

Conditions: Heart Failure
Interventions: CRT-D System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,971 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 71
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 68 more

Conditions: Endometrial Cancer
Interventions: retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 29
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 26 more

Search by objective public record fields.

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1

Just-in-time Adaptive Intervention Messaging in a Digital Weight Loss Intervention for Young Adults

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

Burn Validation Study

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging

Community-associated Highly-Resistant Enterobacterales

Combination Chemotherapy in Treating Children With Neuroblastoma

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Oxytocin Treatment of Opioid Dependence

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities

Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis

Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Nephrotic Syndrome Study Network

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Quadripolar Pacing Post Approval Study

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.